LMTXEarnings•globenewswire•
Larimar Therapeutics Reports Second Quarter 2025 Financial Results
Sentiment:Negative (30)
Summary
*Pro forma cash, cash equivalents, and marketable securities of $203.6 million reflects $138.5 million of cash, cash equivalents and marketable securities as of June 30, 2025 combined with the $65.1 million in net proceeds from the recently completed July 2025 public offering.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 14, 2025 by globenewswire